𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sphincter of Oddi motility disorders in patients with idiopathic recurrent pancreatitis

✍ Scribed by Dr. J. Toouli; I. C. Roberts-Thomson; J. Dent; J. Lee


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
470 KB
Volume
72
Category
Article
ISSN
0007-1323

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Oddi's Sphincter Motor Activity in Patie
✍ Mohammad Sultan Khuroo; Showkat Ali Zargar; Ghulam Nabi Yattoo; Mohammed Sultan πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 646 KB

Oddi's sphincter motor activity was studied in 15 healthy subjects and 15 patients with recurrent pyogenic cholangitis. No significant difference was found in the common bile duct pressures, the Oddi's sphincter basal pressures or the amplitude, frequency and duration of phasic contractions between

Adrenergic control of the internal anal
✍ Mr. C. T. M. Speakman; C. H. V. Hoyle; M. A. Kamm; M. M. Henry; R. J. Nicholls; πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 316 KB πŸ‘ 2 views

## Abstract There is histological and functional evidence that the internal anal sphincter is abnormal in patients with idiopathic faecal incontinence. The in vitro responsiveness of the internal anal sphincter to nor adrenaline (an important sympathetic neurotransmitter) and electrical field stimu

Prevalence estimates of recurrent balanc
✍ Felix Mitelman; Fredrik Mertens; Bertil Johansson πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 195 KB

## Abstract Chromosome abnormalities have been reported in more than 46,000 benign and malignant neoplastic disorders, leading to the identification of numerous recurrent abnormalities. A substantial number of recurrent balanced aberrations (RBAs), in particular, reciprocal translocations, occur wi

Results of imatinib mesylate therapy in
✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated